Free Trial
NYSE:BHC

Bausch Health Cos (BHC) Stock Price, News & Analysis

Bausch Health Cos logo
$8.26 -0.10 (-1.14%)
Closing price 03:59 PM Eastern
Extended Trading
$8.21 -0.05 (-0.59%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bausch Health Cos Stock (NYSE:BHC)

Advanced

Key Stats

Today's Range
$8.24
▼
$8.43
50-Day Range
$5.64
▼
$8.89
52-Week Range
$4.33
▼
$9.04
Volume
2.35 million shs
Average Volume
4.77 million shs
Market Capitalization
$3.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75
Consensus Rating
Reduce

Company Overview

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics.

Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.

The company was known as Valeant Pharmaceuticals International before adopting the Bausch Health name in 2018. Thomas J. Appio has served as its chief executive officer since 2022.

AI Generated. May Contain Errors.

Bausch Health Cos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

BHC MarketRank™: 
2.457273320285 of 5 stars

Bausch Health Cos scored higher than 49% of companies evaluated by MarketBeat, and ranked 573rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch Health Cos has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Bausch Health Cos is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Bausch Health Cos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch Health Cos' stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch Health Cos are expected to decrease by -12.36% in the coming year, from $4.53 to $3.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch Health Cos is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch Health Cos is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    2.50% of the float of Bausch Health Cos has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch Health Cos has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch Health Cos has recently decreased by 10.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bausch Health Cos does not currently pay a dividend.

  • Dividend Growth

    Bausch Health Cos does not have a long track record of dividend growth.

  • News Sentiment

    Bausch Health Cos has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Bausch Health Cos this week, compared to 4 articles on an average week.
  • Search Interest

    8 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Bausch Health Cos to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch Health Cos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,894.00 in company stock.

  • Percentage Held by Insiders

    20.67% of the stock of Bausch Health Cos is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bausch Health Cos' insider trading history.
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Cos and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BHC Stock News Headlines

Bausch Health Cos (NYSE:BHC) Given New $9.00 Price Target at Barclays
$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
See More Headlines

BHC Stock Analysis - Frequently Asked Questions

Bausch Health Cos' stock was trading at $6.95 on January 1st, 2026. Since then, BHC shares have increased by 18.8% and is now trading at $8.2550.

Bausch Health Cos Inc. (NYSE:BHC) posted its quarterly earnings results on Wednesday, October, 28th. The company reported $1.77 EPS for the quarter, beating the consensus estimate of $1.25 by $0.52. The firm had revenue of $2.90 billion for the quarter, compared to analysts' expectations of $2.72 billion. Bausch Health Cos had a negative trailing twelve-month return on equity of 401.73% and a negative net margin of 7.57%.
Read the conference call transcript
.

Top institutional shareholders of Bausch Health Cos include Private Management Group Inc. (0.45%), Chicago Partners Investment Group LLC (0.20%), Cibc World Market Inc. (0.17%) and Lido Advisors LLC (0.10%). Insiders that own company stock include John Paulson, Seana Carson, Aimee J Lenar and Frank D Lee.
View institutional ownership trends
.

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Cos investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Bank of America (BAC).

Company Calendar

Last Earnings
10/28/2026
Today
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:BHC
CIK
885590
Employees
20,300
Year Founded
1959

Price Target and Rating

High Price Target
$10.00
Low Price Target
$8.00
Potential Upside/Downside
+6.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
2.08
P/E Growth
N/A
Net Income
$157 million
Net Margins
-7.57%
Pretax Margin
-3.18%
Return on Equity
-401.73%
Return on Assets
7.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.56
Quick Ratio
1.22

Sales & Book Value

Annual Sales
$10.27 billion
Price / Sales
0.30
Cash Flow
$7.18 per share
Price / Cash Flow
1.15
Book Value
($0.91) per share
Price / Book
-9.07

Miscellaneous

Outstanding Shares
374,400,000
Free Float
296,906,000
Market Cap
$3.09 billion
Optionable
Optionable
Beta
0.30

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NYSE:BHC) was last updated on 11/12/2026 by MarketBeat.com Staff.
From Our Partners